The rarity of sarcoma complicates clinical trial design and biomarker-driven treatment, explains Alexander Spira, MD, PhD, ...
Reimbursement uncertainty and absent permanent billing codes remain dominant CGT access barriers, exposing limitations of “buy-and-bill” models and necessitating dedicated staffing and early ...
From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today. He also explored when a triplet regimen—acalabrutinib, ...
Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...
As oncology care becomes increasingly complex with the introduction of targeted therapies, oncology pharmacists are playing a larger role in translating emerging evidence into clinical practice. Kang: ...
Development is moving to phase 2 LEGION-100-2a (NCT06533644) across global sites, with planned neoadjuvant prostate studies and expansion concepts in multiple solid tumors. Metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results